Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by 294everon Oct 18, 2021 10:59am
197 Views
Post# 34017977

RE:Cash Position

RE:Cash Position

What you're saying makes sense and it's nice that management isn't falsely pumping this stock (refreshing actually). I don't believe however that they are gonna drag a$$ for the next few years and do nothing, they just need some time to regroup and formulate next steps. They got to Phase 3 not by being stupid liars. The science speaks for itself.
These are called trials for a reason. 

Food for thought......


Is it not in management and all insiders best interest to keep the ball rolling so to speak? I mean they all hold shares as well. I don't see an insider sell off happening here. This speaks of confidence in the science and the company. I bought lower than most however in the last week have still seen a 25% loss.....

not 400% but we're still talking substantial amount. Point is I will hold because this is a blip and if anyone can afford it I'd suggest they do as well. I've bought several pharmaceutical stocks that were losers this isn't one of them.

I sincerely wish everyone the best of Luck!


 

<< Previous
Bullboard Posts
Next >>